Johnson & Johnson Seeks FDA Nod for Caplyta in Mania
The company has submitted a supplemental application for bipolar mania, its fifth potential adult indication for the antipsychotic.
Updated on Nov. 19, 2026 in Mental Health

Live Poll
Would you trust a newly approved psychiatric medication for a family member's bipolar disorder?
Johnson & Johnson submitted a supplemental New Drug Application to the FDA for Caplyta to treat bipolar mania. The application is supported by two pivotal phase 3 studies in which the 42 mg dose significantly reduced manic symptoms compared with placebo.
Why it matters
If approved, the treatment would expand Caplyta's adult uses beyond bipolar depression, schizophrenia and adjunctive major depressive disorder treatment. Bipolar disorder affects an estimated 11 million U.S. adults at some point in their lives, so the application addresses a significant population.
The application rests on two randomized, double-blind, placebo-controlled phase 3 studies in which once-daily Caplyta 42 mg reduced manic symptoms versus placebo over three weeks, with improvement appearing as early as day 3. The FDA has not yet acted on the submission, and the mechanism of action of the drug is still unknown.
The players
Johnson & Johnson
A multinational pharmaceutical and medical device company headquartered in New Brunswick, New Jersey, and the developer and marketer of Caplyta.
U.S. Food and Drug Administration
The federal agency responsible for reviewing and approving new drug applications and supplemental applications before medicines can be marketed in the United States.
The details
Johnson & Johnson said both studies met their primary and key secondary endpoints, and Caplyta was well tolerated with low discontinuation rates. Caplyta is an oral, once-daily atypical antipsychotic already approved in adults for bipolar depression, schizophrenia and adjunctive treatment of major depressive disorder.
Timeline
September 15-19, 2026: Phase 3 results presented at Psych Congress 2026.
November 5-8, 2026: Phase 3 results presented at NEI Fall Congress 2026.
November 19, 2026: Johnson & Johnson announced the sNDA submission.
Health Landscape
The submission extends the label of Caplyta, an oral once-daily atypical antipsychotic already approved for bipolar depression, schizophrenia and adjunctive major depressive disorder. If approved, bipolar mania would become its fifth adult indication, widening the drug's role in treating bipolar disorder.
If the FDA approves the application, adults with bipolar mania would have access to a once-daily oral treatment option. Patients and clinicians would need to weigh its reported side-effect and tolerability profile against existing bipolar treatments once a label is issued.
The takeaway
A pending FDA decision could add a new treatment option for bipolar mania, a condition that affects millions of U.S. adults. Readers following the drug should watch for the agency's review outcome and any label details that follow.
Further reading
Explore more coverage in Mental Health for context on bipolar disorder and its treatments.
More information
Read the Johnson & Johnson sNDA news release for the company's full announcement.
Live Poll
Would you trust a newly approved psychiatric medication for a family member's bipolar disorder?






